storage stability comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
=== Other symptoms and comorbidities === Myoglobinuria (reddish-brown urine) may be seen due to the breakdown of skeletal muscle known as rhabdomyolysis (a condition in which muscle cells breakdown, sending their contents into the bloodstream). In 2020, the largest study to-date of 269 GSD-V patients, 39.4% reported no previous episodes of myoglobinuria and 6.8% had normal CK (including those with fixed muscle weakness); so an absence of myoglobinuria and normal CK should not rule out the possibility of the disease. Between 33-51.4% develop fixed muscle weakness, typically of the trunk and upper body, with the onset of muscle weakness usually occurring later in life (40+ years of age). Younger people may display unusual symptoms, such as difficulty chewing, swallowing, or utilizing normal oral motor functions. Idiopathic leg pains were common in children, usually occurring at night, often presumed to be "growing pains" and not investigated further. Several comorbidities were found in GSD-V individuals at a higher rate than in the general population, including (but not limited to): hypertension (17%), endocrine diseases (15.7%), musculoskeletal/rheumatic disease (12.9%), hyperuricemia/gout (11.6%), gastrointestinal diseases (11.2%), neurological disease (10%), respiratory disease (9.5%), and coronary artery disease (8.3%). They may have a pseudoathletic appearance of muscle hypertrophy (24%), particularly of the legs, and may have lower bone mineral content and density in the legs.
The radioactive substance used clinical practices in PET scanning is a simple sugar called fluorodeoxyglucose (FDG). Many different tracers may be used for research or clinical investigations various imaging purposes, depending on the target process within the body, such as:
The lacteals were termed the fourth kind of vessels (the other three being the artery, vein, and nerve, which was then believed to be a type of vessel), disproving Galen's assertion that the veins carried chyle. But, he still believed that the lacteals carried the chyle to the liver (as taught by Galen). He also identified the thoracic duct but failed to notice its connection with the lacteals. This connection was established by Jean Pecquet in 1651, who found a white fluid mixing with blood in a dog's heart. He suspected that the fluid was chyle as its flow increased when abdominal pressure was applied. He traced this fluid to the thoracic duct, which he then followed to a chyle-filled sac he called the chyli receptaculum, which is now known as the cisternae chyli; further investigations led him to find that lacteals' contents enter the venous system via the thoracic duct. Thus, it was proven convincingly that the lacteals did not terminate in the liver, thus disproving Galen's second idea: that the chyle flowed to the liver. Johann Veslingius drew the earliest sketches of the lacteals in humans in 1641. The idea that blood recirculates through the body rather than being produced anew by the liver and the heart was first accepted as a result of the works of William Harvey—a work he published in 1628. In 1652, Olaus Rudbeck (1630–1702) discovered certain transparent vessels in the liver that contained clear fluid (and not white), and thus named them hepatico-aqueous vessels. He also learned that they emptied into the thoracic duct and that they had valves.
A soldier going to battle on Pervitin usually found himself unable to perform effectively for the next day or two. Suffering from a drug hangover and looking more like a zombie than a great warrior, he had to recover from the side effects. Some soldiers turned violent, committing war crimes against civilians; others attacked their own officers. At the end of the war, it was used as part of a new drug: D-IX. Obetrol, patented by Obetrol Pharmaceuticals in the 1950s and indicated for treatment of obesity, was one of the first brands of pharmaceutical methamphetamine products. Because of the psychological and stimulant effects of methamphetamine, Obetrol became a popular diet pill in the United States in the 1950s and 1960s. Eventually, as the addictive properties of the drug became known, governments began to strictly regulate the production and distribution of methamphetamine. For example, during the early 1970s in the United States, methamphetamine became a schedule II controlled substance under the Controlled Substances Act. As of January 2013, the Desoxyn trademark had been sold to Italian pharmaceutical company Recordati.
=== Signalling of fetal maturation and parturition === As pregnancy advances to term, the fetal membranes undergo weakening. The amnion is vital in the synthesis of prostaglandins which reach the myometrium and create and initiate parturition. The chorion expresses chemicals that balance synthesis and metabolism of these prostaglandins to ensure that the myometrium is not activated pre-term. Prostaglandin E2 is thought to be synthesized by cells in the amnion and is essential in dilation of the cervix at the initiation of parturition. Glucocorticoids have been implicated in fetal maturation, regulation of immune response and many other pregnancy associated changes. As well as its function in parturition, Prostaglandin E2 is vital for fetal lung maturation. Additionally, there is an abundance of 11β-hydroxysteroid dehydrogenase 1 expressed in the foetal membranes. This enzyme converts biologically inactive cortisone into active cortisol, another chemical vital for fetal maturation and labour initiation.
Sources: en.wikipedia.org
An important example is the issue of which matrix is used for MALDI spotting, since much of the energetics of the desorption/ionization event is controlled by the matrix rather than the laser power. Sometimes samples are spiked with sodium or another ion-carrying species to produce adducts rather than a protonated species. Mass spectrometry can measure molar mass, molecular structure, and sample purity. Each of these questions requires a different experimental procedure; therefore, adequate definition of the experimental goal is a prerequisite for collecting the proper data and successfully interpreting it.
Cuprate of Tl–Ba–Ca The first series of the Tl-based superconductor containing one Tl–O layer has the general formula TlBa2Can−1CunO2n+3, whereas the second series containing two Tl–O layers has a formula of Tl2Ba2Can−1CunO2n+4 with n =1, 2 and 3. In the structure of Tl2Ba2CuO6 (Tl-2201), there is one CuO2 layer with the stacking sequence (Tl–O) (Tl–O) (Ba–O) (Cu–O) (Ba–O) (Tl–O) (Tl–O). In Tl2Ba2CaCu2O8 (Tl-2212), there are two Cu–O layers with a Ca layer in between. Similar to the Tl2Ba2CuO6 structure, Tl–O layers are present outside the Ba–O layers. In Tl2Ba2Ca2Cu3O10 (Tl-2223), there are three CuO2 layers enclosing Ca layers between each of these. In Tl-based superconductors, Tc is found to increase with the increase in CuO2 layers. However, the value of Tc decreases after four CuO2 layers in TlBa2Can−1CunO2n+3, and in the Tl2Ba2Can−1CunO2n+4 compound, it decreases after three CuO2 layers. Cuprate of Hg–Ba–Ca The crystal structure of HgBa2CuO4 (Hg-1201), HgBa2CaCu2O6 (Hg-1212) and HgBa2Ca2Cu3O8 (Hg-1223) is similar to that of Tl-1201, Tl-1212 and Tl-1223, with Hg in place of Tl. It is noteworthy that the Tc of the Hg compound (Hg-1201) containing one CuO2 layer is much larger as compared to the one-CuO2-layer compound of thallium (Tl-1201). In the Hg-based superconductor, Tc is also found to increase as the CuO2 layer increases. For Hg-1201, Hg-1212 and Hg-1223, the values of Tc are 94, 128, and the record value at ambient pressure 134 K (−139 °C), respectively, as shown in table below.
Nickel is obtained through extractive metallurgy: it is extracted from ore by conventional roasting and reduction processes that yield metal of greater than 75% purity. In many stainless steel applications, 75% pure nickel can be used without further purification, depending on impurities. Traditionally, most sulfide ores are processed using pyrometallurgical techniques to produce a matte for further refining. Hydrometallurgical techniques are also used. Most sulfide deposits have traditionally been processed by concentration through a froth flotation process followed by pyrometallurgical extraction. The nickel matte is further processed with the Sherritt-Gordon process. First, copper is removed by adding hydrogen sulfide, leaving a concentrate of cobalt and nickel. Then, solvent extraction is used to separate the cobalt and nickel, with the final nickel content greater than 86%. A second common refining process is leaching the metal matte into a nickel salt solution, followed by electrowinning the nickel from solution by plating it onto a cathode as electrolytic nickel.
=== Scotland to England in 1984 === He began at the age of 18 at John o' Groats (at the northern tip of Scotland) in 1984, and walked to Land's End in England. On this journey, which he carried out with three other people, he pushed a wheelchair 1,000 miles (1,600 km) and raised £3,500 for The Forelands School for handicapped children. In 1983, he had already run 21 miles (34 km) around a 400-metre track to raise further money for The Forelands School for handicapped children, at Broadstairs in Kent.
== Ion exchange resins == Ion exchange resins are the physical medium that facilitates ion exchange reactions. The resin is composed of cross-linked organic polymers, typically polystyrene matrix and functional groups where the ion exchange process takes place.
Sources: en.wikipedia.org
For services to Music. International list John Adams. Chair, British Retirement Home Association, Portugal. For services to the Community and Voluntary Organisations in Portugal. Joy Atkinson. Desk Officer, Foreign, Commonwealth and Development Office. For services to British Foreign Policy. Nicola Jane Barrett. Head, Corporate Services, British Embassy Moscow, Russia. For services to British Foreign Policy. Liza Barry. Deputy Director, Foreign, Commonwealth and Development Office. For services to National Security. Geoffrey James Booker. Founding Chairman and Field Director, The Quicken Trust and The GB Trust. For services to the community in Kabubbu, Uganda. Geraldine Elizabeth Booker. Director of Development, The Quicken Trust and The GB Trust. For services to the community in Kabubbu, Uganda. Sian Bowsley. Head, Agrifood and Sanitary and Phytosanitary (SPS), Windsor Framework Taskforce, Foreign, Commonwealth and Development Office. For services to British Foreign Policy. Christopher Mark Broadbent. Team Leader, Foreign, Commonwealth and Development Office. For services to National Security. Keith John Buckley. Chairman, British Chamber of Commerce, Macao; Chairman, The Lighthouse Club (Macao Branch) charity. For services to the Local Community and British Interests in Macao. Scott Arthur Burgess. Acting Overseas Security Manager, British Embassy Tehran, Iran. For services to the British Embassy Tehran. Adina Diana Esther Munroe-Charlow. Chairperson, Royal British Legion, Bahamas Branch. For services to Veterans in The Bahamas. Gillian Clasby.
IonSense, Inc. is a Massachusetts-based company that is developing technology for the analysis of materials by direct analysis in real time or DART mass spectrometry. DART MS provides rapid qualitative and quantitative sample analysis of bioanalytical, medicinal, forensic, and chemical synthesis products by ambient mass spectrometry. IonSense provides the DART Ion Sources which are interfaced to mass spectrometry systems manufactured by JEOL, Thermo Fisher Scientific, Bruker, Applied Biosystems, Agilent, and Waters. IonSense was acquired by Bruker in April 2022.
=== Vaccination and information === Modern societies are facing the challenge of "rational" exemption, i.e. the family's decision to not vaccinate children as a consequence of a "rational" comparison between the perceived risk from infection and that from getting damages from the vaccine. In order to assess whether this behavior is really rational, i.e. if it can equally lead to the eradication of the disease, one may simply assume that the vaccination rate is an increasing function of the number of infectious subjects:
=== May === 1 May – Bob Brockie, biologist, cartoonist (National Business Review) and columnist (Dominion Post) (born 1932). 2 May – Sir Bob Jones, property magnate, writer, and politician, founder of the New Zealand Party (1983) (born 1939). 5 May Shane Richardson, motorcycle racer (born c. 1996). Shane Solomon, lawyer and Māori leader (Waikato Tainui) (born 1963). 6 May – Bill McCaw, rugby union player (Southland, national team), oldest living All Black (since 2023) (born 1927). 9 May – Fred Graham, rugby union player (New Zealand Māori), educator and sculptor, Te Tohu mō Te Arikinui Dame Te Atairangikaahu (2017), Arts Foundation of New Zealand Icon (since 2018) (born 1928). 13 May – Danny Lendich, businessman and midget car racing team owner, introduced Wendy's to New Zealand (1988) (born 1944). 14 May – Lionel Hill-Smith, Empire Games hurdler (1950) (born 1929). 15 May – Durham Havill, local politician and businessman, Mayor of Westland (1989–1998) (born 1944). 16 May – Tuppy Diack, rugby union player (Otago, Southland, national team) and administrator, president of the Otago Rugby Football Union (2005) (born 1930). 17 May – Clive Rennie, educator, principal of Rangitikei College (1986–1991), Mountainview High School (1997–2000) and Otago Boys' High School (2000–2014) (born 1944). 18 May – John Simpson, silversmith and fine arts academic (University of Canterbury) (born 1925). 21 May – Frank Gibson Jr., jazz drummer and drum tutor (born 1946). 23 May – Roger Bridge, businessman and political party official (National) (born 1958).
== Distribution and habitat == This species is found in parts of central and western Africa, in Burundi, Cameroon, Central African Republic, Democratic Republic of Congo, Republic of Congo, Equatorial Guinea, Gabon, Rwanda, and the province of Cabinda in Angola, as well as along the Burundian, Tanzanian and Zambian shores of Lake Tanganyika. It is largely an aquatic species and rarely is found far away from water. It can be found along lakes and rivers in forested and well-wooded savanna terrain where cover is sufficient, most commonly along lowland forested, bushy or wooded banks of lakes, rivers, and streams.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.